Bosentan therapy for cutaneous fibrosis in systemic sclerosis

References

• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90
   PubMed Web of Science ®Google Scholar
• Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998;17:48–54
   PubMed Web of Science ®Google Scholar
• Clements PJ. Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 1995;7:517–21
   PubMedGoogle Scholar
• Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27–31
   PubMedGoogle Scholar
• Richards HL, Herrick AL, Griffin K, et al. Systemic sclerosis: patients’ perceptions of their condition. Arthritis Rheum 2003;49:689–96
   PubMed Web of Science ®Google Scholar
• Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2003;2:181–91
   PubMed Web of Science ®Google Scholar
• Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255–63
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5
   PubMed Web of Science ®Google Scholar
• Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445–54
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA, Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828–35
   Google Scholar
• Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002;138:99–105
   PubMed Web of Science ®Google Scholar
• Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194–1203
   PubMed Web of Science ®Google Scholar
• Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998;139:639–48
   PubMed Web of Science ®Google Scholar
• Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:299–305
   PubMed Web of Science ®Google Scholar
• Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871–9
   PubMed Web of Science ®Google Scholar
• Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003;48: 1190–9
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Suzuki K, Hara M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994;53:506–10
   PubMed Web of Science ®Google Scholar
• Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978–83
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116: 417–25
   Google Scholar
• Yamane K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992;19:1566–71
   PubMed Web of Science ®Google Scholar
• Kadono T, Kikuchi K, Sato S, et al. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995;287: 439–42
   PubMed Web of Science ®Google Scholar
• Morelli S, Ferri C, Polettini E, et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995;99:255–60
   PubMed Web of Science ®Google Scholar
• Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets – a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838–44
   PubMed Web of Science ®Google Scholar
• Vancheeswaran R, Azam A, Black C, et al. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268–76
   PubMed Web of Science ®Google Scholar
• Denton C, Humbert M, Rubin L, et al. Bosentan therapy for pulmonary arterial hypertension related to systemic sclerosis: a subgroup analysis of the pivotal studies and their extensions. Ann Rheum Dis 2005;64:294
   Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346: 896–903
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244–9
   PubMed Web of Science ®Google Scholar
• Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926–32
   PubMed Web of Science ®Google Scholar
• Korn JH, Mayes M, Matucci CM, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985–93
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Nardi N, et al. Successful treatment of severe Raynaud’s phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (Oxford) 2004;43:1454–6
   PubMed Web of Science ®Google Scholar
• Launay D, Diot E, Pasquier E, et al. Bosentan for treatment of active digital ulcers in patients with systemic sclerosis. Presse Med 2006;35:587–92
   PubMed Web of Science ®Google Scholar
• Tillon J, Herve F, Chevallier D, et al. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy. Br J Dermatol 2006;154:1000–2
   PubMed Web of Science ®Google Scholar
• Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford) 2003;42:191–3
   PubMed Web of Science ®Google Scholar
• Alegre-Sancho JJ, Román-Ivorra JA, Fernandez-Carballido C, et al. Systemic sclerosis: improvements of cutaneous fibrosis on bosentan therapy. Ann Rheum Dis 2004;63(Suppl I):339 [abstract]
   Google Scholar
• Brennan P, Silman A, Black C, et al. Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol 1992;31:457–60
   PubMed Web of Science ®Google Scholar
• Merkel PA, Clements PJ, Reveille JD, et al. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630–47
   PubMed Web of Science ®Google Scholar
• Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22: 1281–5
   PubMed Web of Science ®Google Scholar
• Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84–8
   PubMed Web of Science ®Google Scholar